company background image
UBI

Universal Biosensors ASX:UBI Stock Report

Last Price

AU$0.26

Market Cap

AU$55.1m

7D

0%

1Y

-65.8%

Updated

06 Oct, 2022

Data

Company Financials +
UBI fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

UBI Stock Overview

Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company primarily in Australia.

Universal Biosensors Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Universal Biosensors
Historical stock prices
Current Share PriceAU$0.26
52 Week HighAU$1.04
52 Week LowAU$0.22
Beta1.26
1 Month Change-10.35%
3 Month Change-26.76%
1 Year Change-65.79%
3 Year Change40.54%
5 Year Change-31.58%
Change since IPO-74.00%

Recent News & Updates

Shareholder Returns

UBIAU Medical EquipmentAU Market
7D0%0.9%3.8%
1Y-65.8%-15.6%-7.1%

Return vs Industry: UBI underperformed the Australian Medical Equipment industry which returned -15.6% over the past year.

Return vs Market: UBI underperformed the Australian Market which returned -7.1% over the past year.

Price Volatility

Is UBI's price volatile compared to industry and market?
UBI volatility
UBI Average Weekly Movement11.1%
Medical Equipment Industry Average Movement11.0%
Market Average Movement9.4%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market4.3%

Stable Share Price: UBI is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: UBI's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200181John Sharmanhttps://www.universalbiosensors.com

Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company primarily in Australia. The company focuses on the development, manufacture, and commercialization of point-of-use devices for measuring analytes across various industries. It manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips; and distributes Siemens’ Xprecia Stride Coagulation Analyzer, a test used to monitor the effect of the anticoagulant therapy warfarin.

Universal Biosensors Fundamentals Summary

How do Universal Biosensors's earnings and revenue compare to its market cap?
UBI fundamental statistics
Market CapAU$55.08m
Earnings (TTM)-AU$16.48m
Revenue (TTM)AU$5.47m

10.1x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
UBI income statement (TTM)
RevenueAU$5.47m
Cost of RevenueAU$3.48m
Gross ProfitAU$1.98m
Other ExpensesAU$18.46m
Earnings-AU$16.48m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.078
Gross Margin36.29%
Net Profit Margin-301.22%
Debt/Equity Ratio0.7%

How did UBI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is UBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UBI?

Other financial metrics that can be useful for relative valuation.

UBI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.3x
Enterprise Value/EBITDA-1.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does UBI's PS Ratio compare to its peers?

UBI PS Ratio vs Peers
The above table shows the PS ratio for UBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average20.3x
CSX CleanSpace Holdings
3.6x23.5%AU$48.5m
RSH Respiri
38.6x79.1%AU$29.7m
CMP Compumedics
1.1xn/aAU$42.5m
IMR Imricor Medical Systems
37.7x86.2%AU$50.7m
UBI Universal Biosensors
10.1x75.7%AU$55.1m

Price-To-Sales vs Peers: UBI is good value based on its Price-To-Sales Ratio (10.1x) compared to the peer average (20.3x).


Price to Earnings Ratio vs Industry

How does UBI's PE Ratio compare vs other companies in the AU Medical Equipment Industry?

Price-To-Sales vs Industry: UBI is expensive based on its Price-To-Sales Ratio (10.1x) compared to the Australian Medical Equipment industry average (7.2x)


Price to Sales Ratio vs Fair Ratio

What is UBI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UBI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.1x
Fair PS Ratio23.7x

Price-To-Sales vs Fair Ratio: UBI is good value based on its Price-To-Sales Ratio (10.1x) compared to the estimated Fair Price-To-Sales Ratio (23.7x).


Share Price vs Fair Value

What is the Fair Price of UBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UBI (A$0.26) is trading below our estimate of fair value (A$13.94)

Significantly Below Fair Value: UBI is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Universal Biosensors forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


91.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: UBI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).

Earnings vs Market: UBI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: UBI is expected to become profitable in the next 3 years.

Revenue vs Market: UBI's revenue (75.7% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: UBI's revenue (75.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: UBI's Return on Equity is forecast to be low in 3 years time (2.3%).


Discover growth companies

Past Performance

How has Universal Biosensors performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-46.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: UBI is currently unprofitable.

Growing Profit Margin: UBI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: UBI is unprofitable, and losses have increased over the past 5 years at a rate of 46.7% per year.

Accelerating Growth: Unable to compare UBI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UBI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-25.3%).


Return on Equity

High ROE: UBI has a negative Return on Equity (-37.81%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Universal Biosensors's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: UBI's short term assets (A$44.3M) exceed its short term liabilities (A$11.1M).

Long Term Liabilities: UBI's short term assets (A$44.3M) exceed its long term liabilities (A$10.4M).


Debt to Equity History and Analysis

Debt Level: UBI has more cash than its total debt.

Reducing Debt: UBI's debt to equity ratio has reduced from 121% to 0.7% over the past 5 years.

Debt Coverage: UBI's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if UBI's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Dividend

What is Universal Biosensors's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Universal Biosensors Dividend Yield vs Market
How does Universal Biosensors dividend yield compare to the market?
SegmentDividend Yield
Company (Universal Biosensors)n/a
Market Bottom 25% (AU)2.7%
Market Top 25% (AU)6.9%
Industry Average (Medical Equipment)1.8%
Analyst forecast in 3 Years (Universal Biosensors)n/a

Notable Dividend: Unable to evaluate UBI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UBI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UBI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UBI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as UBI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

John Sharman (56 yo)

2.75yrs

Tenure

AU$3,466,500

Compensation

Mr. John Stewart Sharman, M.App.Fin, CA, B Ec, serves as Chief Executive Officer at Universal Biosensors, Inc. since 2020. He served as Non-Executive Director at Cann Group Limited from April 27, 2021 to S...


CEO Compensation Analysis

John Sharman's Compensation vs Universal Biosensors Earnings
How has John Sharman's remuneration changed compared to Universal Biosensors's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-AU$16m

Mar 31 2022n/an/a

-AU$14m

Dec 31 2021AU$3mAU$480k

-AU$11m

Sep 30 2021n/an/a

-AU$7m

Jun 30 2021n/an/a

-AU$6m

Mar 31 2021n/an/a

-AU$8m

Dec 31 2020AU$696kAU$271k

-AU$8m

Compensation vs Market: John's total compensation ($USD2.24M) is above average for companies of similar size in the Australian market ($USD276.12K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: UBI's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: UBI's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: UBI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

ASX:UBI Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
17 Aug 22BuyAU$80,954Craig ColemanIndividual200,000AU$0.40
06 Jul 22SellAU$1,091,432JM Financial Asset Management LimitedCompany2,946,208AU$0.42
23 Jun 22BuyAU$1,986,067Richmond Hill Capital Pty LtdCompany3,697,600AU$0.54
16 Jun 22BuyAU$895,113Richmond Hill Capital Pty LtdCompany1,825,925AU$0.49
09 Jun 22BuyAU$13,349Craig ColemanIndividual25,000AU$0.53
06 Jun 22SellAU$124,680JM Financial Asset Management LimitedCompany276,432AU$0.45
01 Jun 22BuyAU$46,000Graham McLeanIndividual100,000AU$0.46
27 May 22BuyAU$556,800Viburnum Funds Pty Ltd.Company1,280,000AU$0.43
27 May 22BuyAU$23,338Craig ColemanIndividual48,620AU$0.48
27 May 22BuyAU$778,351Viburnum Funds Pty Ltd.Company1,280,000AU$0.61
27 May 22BuyAU$7,700Craig ColemanIndividual10,000AU$0.77
27 May 22BuyAU$10,764Craig ColemanIndividual10,000AU$1.08
27 May 22BuyAU$27,871,449Viburnum Funds Pty Ltd.Company25,893,617AU$1.08
27 May 22BuyAU$33,723Judith SmithIndividual43,796AU$0.77
27 May 22BuyAU$796,803Viburnum Funds Pty Ltd.Company1,000,000AU$0.80
24 May 22BuyAU$33,013Craig ColemanIndividual48,620AU$0.68
17 May 22SellAU$1,522,246Jencay Capital Pty LtdCompany1,671,717AU$0.91
12 May 22BuyAU$49,994Graham McLeanIndividual100,000AU$0.50
09 May 22BuyAU$26,000JM Financial Asset Management LimitedCompany50,000AU$0.52
04 May 22BuyAU$1,684,425Richmond Hill Capital Pty LtdCompany2,607,980AU$0.65
02 May 22SellAU$1,171,007JM Financial Asset Management LimitedCompany1,721,371AU$0.99
08 Mar 22SellAU$1,883,551JM Financial Asset Management LimitedCompany2,141,467AU$0.88
03 Feb 22BuyAU$54,493JM Financial Asset Management LimitedCompany61,889AU$0.88
05 Nov 21BuyAU$1,371,744Viburnum Funds Pty Ltd.Company1,378,757AU$1.01

Ownership Breakdown

What is the ownership structure of UBI?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,258,6051.1%
Institutions52,786,05824.9%
VC/PE Firms55,798,60126.3%
General Public101,001,17147.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.1%.


Top Shareholders

Top 11 shareholders own 52.32% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
26.34%
Viburnum Funds Pty Ltd.
55,798,601A$14.5m94.93%3.1%
7.68%
Bendigo and Adelaide Bank Limited, Asset Management Arm
16,260,387A$4.2m-30.35%1.77%
7.25%
Jencay Capital Pty Ltd
15,353,028A$4.0m-9.82%10.32%
5.04%
Richmond Hill Capital Pty Ltd
10,685,532A$2.8m27.64%4.3%
4.95%
JM Financial Asset Management Limited
10,487,111A$2.7m-21.93%0.99%
0.27%
David Hoey
566,414A$147.3k0%no data
0.24%
Craig Coleman
503,620A$130.9k65.87%no data
0.16%
Judith Smith
343,796A$89.4k14.6%no data
0.16%
Salesh Balak
338,558A$88.0k0.59%no data
0.14%
John Sharman
306,217A$79.6k0%no data
0.094%
Graham McLean
200,000A$52.0k0%no data

Company Information

Universal Biosensors, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Universal Biosensors, Inc.
  • Ticker: UBI
  • Exchange: ASX
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: AU$55.080m
  • Shares outstanding: 211.84m
  • Website: https://www.universalbiosensors.com

Number of Employees


Location

  • Universal Biosensors, Inc.
  • 1 Corporate Avenue
  • Rowville
  • Victoria
  • 3178
  • Australia


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UBIASX (Australian Securities Exchange)YesNPV (CDI)AUAUDDec 2006
UBICHIA (Chi-X Australia)YesNPV (CDI)AUAUDDec 2006

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/06 00:00
End of Day Share Price2022/10/06 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.